ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors [Yahoo! Fi...
ImmuCell Corporation (ICCC)
US:NASDAQ Investor Relations:
immucell.com/investors
Company Research
Source: Yahoo! Finance
animal health biologics company that develops and markets products to improve calf health and productivity, announced that Dr. Gilles Guillemette and Dr. Anthony DiMarco have been appointed to its Board of Directors, effective April 15, 2026. The Company also announced it is moving to a 7-person Board of Directors with six Independent Directors and the CEO, and that it will create a Strategy and Technology Committee of the Board of Directors. Dr. Guillemette has more than 30 years of executive experience in animal health therapeutics. He has held executive positions at Elanco, Bayer, Henry Schein, Chewy, and Trupanion, where he had significant P&L responsibilities, led strategy, business development and finance functions, and managed regulated therapeutic operations. Dr. Guillemette is currently an Operating Partner at Archimed and earned his Doctor of Veterinary Medicine in Nantes, France. He will Chair the new Strategy and Technology Committee and serve on the Audit Committee. D
Show less
Read more
Impact Snapshot
Event Time:
ICCC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ICCC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ICCC alerts
High impacting ImmuCell Corporation news events
Weekly update
A roundup of the hottest topics
ICCC
News
- ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent DirectorsGlobeNewswire
- Stocks to watch after market on Wednesday: ICCC, COST, STZ [Seeking Alpha]Seeking Alpha
- ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results [Yahoo! Finance]Yahoo! Finance
- ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales ResultsGlobeNewswire
- ImmuCell (ICCC) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "hold (c-)" to "sell (d-)".MarketBeat
ICCC
Sec Filings
- 4/16/26 - Form 4
- 4/16/26 - Form 4
- 4/16/26 - Form 4
- ICCC's page on the SEC website